Spotlight On... Unilife CEO resigns from drug delivery device company amid post-Amgen deal reorg; Greatbatch completes publicly traded neurostim spinoff; HeartWare adds investor to board; and more...

On the heels of a much-needed alliance with Amgen ($AMGN) which gave it a cash lifeline, drug delivery device specialist Unilife ($UNIS) has entered restructure mode. The struggling York, PA, company announced that its CEO, Alan Shortall, and COO, Dr. Ramin Mojdeh, have resigned. Executive search firm Heidrick & Struggles will be searching for a permanent CEO, while senior vice president and general counsel John Ryan takes the helm as interim CEO. He will be helped by a new executive leadership team. In addition, the company now has two business units: Wearable and Auto Injectors and Prefilled Syringes. More

@FierceMedDev: San Diego startup raises $25M+ for prostate cancer genomics just after launch of latest test. Article | Follow @FierceMedDev

@EmilyWFierce: $WOOF charges ahead with $344M deal for vet hospital chain CAPNA. FierceAnimalHealth story | Follow @EmilyWFierce

> The FDA has cleared the instruments and reloads for the da Vinci Xi EndoWrist Stapler 30 from Intuitive Surgical ($ISRG). More

> Miniaturized circulatory support player HeartWare ($HTWR) has added Chadwick Cornell, managing director at private equity firm Goldner Hawn Johnson & Morrison. He was previously the VP of Corporate Development at Medtronic ($MDT). The move comes as the company has been working to appease activist investors. More

> Greatbatch ($GB) has completed its spinout of neurostimulation company Nuvectra ($NVTR). More

Biotech News

@FierceBiotech: Google backs Cambridge epigenetics spinoff in a $21M round. Article | Follow @FierceBiotech

@JohnCFierce: NEJM correction acknowledges CAR developers Dario Campana and Chihaya Imai. More | Follow @JohnCFierce

> Biotech unicorn Stemcentrx is reportedly up for a multibillion-dollar sale. Article

> Battered PTC hits reset on its DMD ambitions in Canada. More

> GW Pharma soars as its cannabis-derived drug aces Phase III. Report

Pharma News

@FiercePharma: ICYMI: VA to stop restricting hep C drugs, offering them to all infected veterans. More | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Vertex, committed to continuous manufacturing, has Hovione build plant to complement the one it already has. Article | Follow @EricPFierce

@CarlyHFierce: Teva speeds toward Allergan deal close with EU thumbs up. Report | Follow @CarlyHFierce

> Pfizer wins stay from Indian court after regulator bans popular cough syrups. News

> Hospitals join drug price-fighting battalion with plans to crack down on spending. More

Animal Health News

> Figo brings home $4M to spur development of mobile tech for pet owners. Story

> Ceva makes strides toward animal health dominance with strong 2015 sales. Article

> VCA charges ahead with $344M deal for vet hospital chain CAPNA. Report

> Head of FDA's Veterinary Medicine program moves to greener pastures. Item

> Zoetis and Merial ink pact to market drugs and vaccines for dairy cattle in India. News

Biotech IT News

> Medidata stutters in attempt to recoup $4.8M in wire fraud losses. Item

> Ambry starts genetic data dump with release of 10,000 exome cancer repository. More

> Genstar flips eClinical player ERT to Nordic Capital for 8-times return. Report

> Boehringer signs up to use Genedata biologics R&D data platform. Story

> PatientsLikeMe taps AstraZeneca, Roche for cash to fuse outcomes, clinical and molecular data. Article

Pharma Marketing News

> Pfizer widens Xalkori's reach with another targeted lung cancer approval. Report

> Novo's combo med Xultophy set for blockbuster-plus sales, analyst figures. More

> India reclears Roche's Avastin for off-label eye sales. Item

> Merck's Keytruda held back by docs who don't want to wait for diagnostics. Story

> Sarilumab's new Humira-beating data poses another threat to AbbVie's megablockbuster sales. Article

Suggested Articles

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.

In one of the longest studies to date in high-risk heart disease, researchers found no significant difference in death rates over more than 10 years.